Analytical Data
-
Gene name
MAGEA4
- Application
-
Alternative Names
Cancer/testis antigen 1.4 (CT1.4) (MAGE-4 antigen) (MAGE-41 antigen) (MAGE-X2 antigen)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43358
-
Expression Region
1-317aa(A173T)
-
Molecular Weight
42.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEA4, a member of the MAGE (Melanoma Antigen Gene) family, is a cancer-testis (CT) antigen predominantly expressed in various tumors while remaining silent in normal tissues except for the testis. The expression of MAGEA4 in cancer cells has garnered significant interest due to its potential role in the immune response, making it a promising target for cancer immunotherapy. Researchers have focused on the recombinant production of MAGEA4 to explore its biological properties and immunogenicity. By generating recombinant MAGEA4 protein, scientists aim to identify the epitopes recognized by T cells, facilitating the development of MAGEA4-based vaccines and immunotherapies. Additionally, studying the protein's structure and function can provide insights into tumor biology and the mechanisms of immune evasion employed by cancer cells. Overall, the investigation of MAGEA4 recombinant protein is crucial for advancing personalized cancer treatment strategies and improving patient outcomes in various malignancies.
